Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NextRNA Therapeutics

Request full access

Committed to develop the next wave of RNA-targeted therapeutics

Cambridge, United StatesFounded 2020Biotech & Life Sciences

About NextRNA Therapeutics

NextRNA Therapeutics, Inc. was a biotechnology firm established in January 2021, which has since ceased operations as of August 2025. The company was co-founded by Chief Executive Officer Dominique Verhelle, Ph.D., MBA, along with Carl Novina, M.D., Ph.D., and Leon Wert Lamas, based on pioneering research from Dr. Novina's lab at the Dana-Farber Cancer Institute. Dr. Verhelle brought over two decades of experience in biopharma and venture capital, including leadership roles at Takeda, Third Rock Ventures, Pfizer, and Celgene, where she focused on epigenetics and drug discovery.

The company's business was centered on the burgeoning field of long non-coding RNAs (lncRNAs), which are RNA molecules that do not code for proteins but are crucial in regulating cellular processes. NextRNA's core strategy was to identify disease-causing interactions between lncRNAs and their associated RNA-binding proteins (RBPs) and then develop selective small molecule drugs to disrupt these pathological connections. This approach offered the optionality to target either the lncRNA itself or the protein it interacts with, aiming to create a new class of therapeutics. The company's proprietary drug discovery engine combined a computational platform, NextMap™, with deep biological expertise to systematically find and validate these novel targets.

NextRNA's primary therapeutic focus areas were oncology and neuroscience, with initial lead programs underway in oncology and immunology. The company's business model relied on venture capital funding and strategic partnerships with larger pharmaceutical companies to advance its pipeline. A major milestone was its public launch in March 2022, backed by $56.1 million raised through a seed round and a Series A financing led by investors like Cobro Ventures and Lightchain Capital. In August 2024, NextRNA entered a significant collaboration with Bayer, potentially worth up to $547 million, to jointly develop two first-in-class small molecule programs in oncology. However, the company ceased operations after facing challenges that included difficult market conditions and a delay in achieving a critical milestone within the Bayer partnership.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
60.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Mar 2022 $47M $187M Lightchain Capital · Evans Capital · Jefferies Group · Rivas Capital ↗
SEEDOther financing Mar 2022 $9.3M $37M Jefferies Group · Lightchain Capital · Evans Capital · Circle Squared Alternative Investment ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

NextRNA Therapeutics website traffic

Latest recorded traffic for NextRNA Therapeutics is 730 monthly website visits, down 61.6% over the last three months. NextRNA Therapeutics's team declined 40% over the past year.

Latest monthly visits730 3-month web change-61.6% 1-year team growth-40%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NextRNA Therapeutics in the Cambridge ecosystem

Live from Dealroom

The NextRNA Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Cobro Ventures

Series A7 investors entered at this stage

  • Lightchain-capital
  • Lightchain Capital
  • Evans Capital
  • Jefferies Group
  • Rivas Capital
  • Willett Advisors
  • Circle Squared Alternative Investment

Other known investors1 additional known investor

  • Dana-Farber Cancer Institute
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NextRNA Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NextRNA Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.